BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24528179)

  • 1. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
    Coutre SE; Othus M; Powell B; Willman CL; Stock W; Paietta E; Levitan D; Wetzler M; Attar EC; Altman JK; Gore SD; Maher T; Kopecky KJ; Tallman MS; Larson RA; Appelbaum FR
    Br J Haematol; 2014 May; 165(4):497-503. PubMed ID: 24528179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of acute promyelocytic leukemia treated with all-
    Abaza Y; Kantarjian H; Garcia-Manero G; Estey E; Borthakur G; Jabbour E; Faderl S; O'Brien S; Wierda W; Pierce S; Brandt M; McCue D; Luthra R; Patel K; Kornblau S; Kadia T; Daver N; DiNardo C; Jain N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Estrov Z; Foudray M; McCue D; Cortes J; Ravandi F
    Blood; 2017 Mar; 129(10):1275-1283. PubMed ID: 28003274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
    Powell BL; Moser B; Stock W; Gallagher RE; Willman CL; Stone RM; Rowe JM; Coutre S; Feusner JH; Gregory J; Couban S; Appelbaum FR; Tallman MS; Larson RA
    Blood; 2010 Nov; 116(19):3751-7. PubMed ID: 20705755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
    Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
    Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.
    Au WY; Kumana CR; Lee HK; Lin SY; Liu H; Yeung DY; Lau JS; Kwong YL
    Blood; 2011 Dec; 118(25):6535-43. PubMed ID: 21998212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
    Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
    Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
    Kutny MA; Alonzo TA; Gerbing RB; Wang YC; Raimondi SC; Hirsch BA; Fu CH; Meshinchi S; Gamis AS; Feusner JH; Gregory JJ
    J Clin Oncol; 2017 Sep; 35(26):3021-3029. PubMed ID: 28767288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
    Ravandi F; Estey E; Jones D; Faderl S; O'Brien S; Fiorentino J; Pierce S; Blamble D; Estrov Z; Wierda W; Ferrajoli A; Verstovsek S; Garcia-Manero G; Cortes J; Kantarjian H
    J Clin Oncol; 2009 Feb; 27(4):504-10. PubMed ID: 19075265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
    Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
    Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of arsenic trioxide in acute promyelocytic leukemia.
    Iland HJ; Seymour JF
    Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
    Shen ZX; Shi ZZ; Fang J; Gu BW; Li JM; Zhu YM; Shi JY; Zheng PZ; Yan H; Liu YF; Chen Y; Shen Y; Wu W; Tang W; Waxman S; De Thé H; Wang ZY; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5328-35. PubMed ID: 15044693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
    Huang H; Qin Y; Xu R; You X; Teng R; Yang L; Xu M; Liu H
    Leuk Res; 2012 Jul; 36(7):841-5. PubMed ID: 22534100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
    Gore SD; Gojo I; Sekeres MA; Morris L; Devetten M; Jamieson K; Redner RL; Arceci R; Owoeye I; Dauses T; Schachter-Tokarz E; Gallagher RE
    J Clin Oncol; 2010 Feb; 28(6):1047-53. PubMed ID: 20085935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
    Chen L; Zhu HM; Li Y; Liu QF; Hu Y; Zhou JF; Jin J; Hu JD; Liu T; Wu DP; Chen JP; Lai YR; Wang JX; Li J; Li JY; Du X; Wang X; Yang MZ; Yan JS; Ouyang GF; Liu L; Hou M; Huang XJ; Yan XJ; Xu D; Li WM; Li DJ; Lou YJ; Wu ZJ; Niu T; Wang Y; Li XY; You JH; Zhao HJ; Chen Y; Shen Y; Chen QS; Chen Y; Li J; Wang BS; Zhao WL; Mi JQ; Wang KK; Hu J; Chen Z; Chen SJ; Li JM
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33495363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
    N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
    Long ZJ; Hu Y; Li XD; He Y; Xiao RZ; Fang ZG; Wang DN; Liu JJ; Yan JS; Huang RW; Lin DJ; Liu Q
    PLoS One; 2014; 9(8):e104610. PubMed ID: 25122165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.